Microbot Medical Inc. (NASDAQ:MBOT - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Microbot Medical in a research report issued on Tuesday, June 10th. HC Wainwright analyst R. Selvaraju expects that the biotechnology company will post earnings per share of ($0.07) for the quarter. HC Wainwright has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Microbot Medical's current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Microbot Medical's Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.23) EPS.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last issued its quarterly earnings data on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.07.
Microbot Medical Stock Down 1.6%
Shares of NASDAQ:MBOT traded down $0.04 during midday trading on Wednesday, reaching $2.46. The company's stock had a trading volume of 523,888 shares, compared to its average volume of 1,721,383. The stock has a fifty day moving average of $2.42 and a 200 day moving average of $1.84. The firm has a market capitalization of $89.49 million, a PE ratio of -3.07 and a beta of 1.14. Microbot Medical has a twelve month low of $0.82 and a twelve month high of $3.38.
Institutional Trading of Microbot Medical
Large investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in Microbot Medical by 7.9% in the 4th quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock valued at $160,000 after acquiring an additional 10,442 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Microbot Medical in the 4th quarter valued at $118,000. Goldman Sachs Group Inc. purchased a new stake in shares of Microbot Medical during the first quarter worth approximately $57,000. Finally, Virtu Financial LLC acquired a new stake in Microbot Medical in the first quarter valued at about $42,000. Hedge funds and other institutional investors own 16.30% of the company's stock.
Microbot Medical Company Profile
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Featured Stories
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
